These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 26698298

  • 21. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, Holtzman DM, Morris JC, Goate AM, Dougherty JD, Cruchaga C.
    BMC Neurol; 2016 Nov 10; 16(1):217. PubMed ID: 27832767
    [Abstract] [Full Text] [Related]

  • 22. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Lleó A, Johannsen P, Freund-Levi Y, Frölich L, Vandenberghe R, Westwood S, Dobricic V, Barkhof F, Legido-Quigley C, Bertram L, Lovestone S, Streffer J, Andreasson U, Blennow K, Zetterberg H, Visser PJ.
    Alzheimers Dement; 2019 May 10; 15(5):644-654. PubMed ID: 30853464
    [Abstract] [Full Text] [Related]

  • 23. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 May 10; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 24. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.
    J Alzheimers Dis; 2012 May 10; 29(1):229-38. PubMed ID: 22232006
    [Abstract] [Full Text] [Related]

  • 25. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A, Mouton-Liger F, Martinet M, Cognat E, Hourregue C, Dumurgier J, Bouaziz-Amar E, Brinkmalm A, Blennow K, Zetterberg H, Hugon J, Paquet C.
    Alzheimers Res Ther; 2022 May 23; 14(1):71. PubMed ID: 35606871
    [Abstract] [Full Text] [Related]

  • 26. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 23; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 27. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.
    Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Dubois B, Floris R, Garaci F, Lista S, Alzheimer Precision Medicine Initiative (APMI).
    Alzheimers Dement; 2018 Apr 23; 14(4):492-501. PubMed ID: 29328927
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2016 May 01; 73(5):561-71. PubMed ID: 27018940
    [Abstract] [Full Text] [Related]

  • 29. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K, Kern S, Zettergren A, Börjesson-Hansson A, Zetterberg H, Skoog I, Blennow K.
    Transl Psychiatry; 2017 Jan 10; 7(1):e995. PubMed ID: 28072416
    [Abstract] [Full Text] [Related]

  • 30. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K.
    Alzheimers Dement; 2015 Oct 10; 11(10):1180-90. PubMed ID: 25533203
    [Abstract] [Full Text] [Related]

  • 31. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 32. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.
    Neuroimage Clin; 2015 Dec 15; 7():598-604. PubMed ID: 25844314
    [Abstract] [Full Text] [Related]

  • 33. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.
    Neurobiol Aging; 2015 Feb 15; 36(2):601-7. PubMed ID: 25435336
    [Abstract] [Full Text] [Related]

  • 34. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 15; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 35. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L, Gao T, Cai T, Li K, Zheng P, Liu J, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2020 Jan 10; 715():134658. PubMed ID: 31794792
    [Abstract] [Full Text] [Related]

  • 36. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
    Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K.
    Brain Res; 2010 Nov 29; 1362():13-22. PubMed ID: 20875798
    [Abstract] [Full Text] [Related]

  • 37. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.
    Muszyński P, Kulczyńska-Przybik A, Borawska R, Litman-Zawadzka A, Słowik A, Klimkowicz-Mrowiec A, Pera J, Dziedzic T, Mroczko B.
    J Alzheimers Dis; 2017 Nov 29; 59(3):903-912. PubMed ID: 28697565
    [Abstract] [Full Text] [Related]

  • 38. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 39. CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.
    Jurasova V, Andel R, Katonova A, Veverova K, Zuntychova T, Horakova H, Vyhnalek M, Kolarova T, Matoska V, Blennow K, Hort J.
    Alzheimers Res Ther; 2024 Sep 06; 16(1):199. PubMed ID: 39242539
    [Abstract] [Full Text] [Related]

  • 40. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.
    J Alzheimers Dis; 2015 Sep 06; 44(2):625-33. PubMed ID: 25322924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.